Targeted therapies can alleviate HER2+ BC, mainly anti-HER2 antibodies such as trastuzumab and pertuzumab, and small molecule tyrosine kinase inhibitors (TKI), such as lapatinib and neratinib (8). Here, ERBB2 is linked to breast cancer.